Kai KupferschmidtAfter months in the doldrums, one of the world’s largest trials of COVID-19 treatments is finally restarting.
Solidarity, a global study led by the World Health Organization (WHO), will test three new drugs in hospitalized COVID-19 patients: the cancer drug imatinib, an antibody named infliximab that is used to treat autoimmune diseases, and artesunate, an antimalarial.The medicines have been shipped to Finland, the first country to have all approvals in place, says John-Arne Røttingen of the Norwegian Institute of Public Health, who chairs the study’s executive group. “I expect that the first patients will probably be recruited there any day,” he says.